Do Active Methamphetamine Users Discount Future, Past, Uncertain, and Other People’s Rewards Differently? A 65-Person Study

Short answer: In a study of 65 adults, researchers found greater discounting of hypothetical future, past, uncertain, and socially distant monetary outcomes among 30 active, non-treatment-seeking methamphetamine users than among 35 nonusing controls. That is a finding about group differences in a behavioral-economic experiment—not proof that methamphetamine caused a particular decision, that every participant had impaired judgment, or that a person’s blood contained any particular methamphetamine concentration.

The study by Richard Yi, Anne E. Carter, and Reid D. Landes, Restricted psychological horizon in active methamphetamine users: future, past, probability, and social discounting, appeared in Behavioural Pharmacology in 2012. Its original source is available through the primary research DOI. The paper is especially informative because it did not treat “impulsivity” as one interchangeable laboratory score. It asked whether different kinds of psychological distance produce similar patterns—and documented meaningful exceptions.

What was the scientific question?

People make choices about outcomes separated from them in several ways. A reward may arrive next year rather than now. A remembered reward may belong to a distant rather than a recent past. A reward may be uncertain rather than guaranteed. A benefit may accrue to an acquaintance instead of oneself. The researchers considered these distinct distances, then tested whether adults actively using methamphetamine assigned less present value to more psychologically distant hypothetical rewards.

They called this idea a restricted psychological horizon. It is a theoretical account of valuation, not a psychiatric diagnosis or a laboratory determination of intoxication. A horizon is “restricted” in this account when a distant consequence contributes comparatively little to a person’s present choice. The study compared distributions and model parameters between groups; it did not derive an operational cutoff for assessing any one witness, defendant, patient, or driver.

Who actually participated?

The independent biological sample was 65 adults: 30 methamphetamine users and 35 nonusing controls. The user group reported methamphetamine as its primary abused drug, use at least weekly for at least a year, and DSM-IV amphetamine-dependence criteria. These were active users not seeking treatment, an important distinction from studies restricted to people already abstinent or enrolled in treatment.

The groups were not randomized to use methamphetamine. Their histories existed before recruitment. Consequently, differences in questionnaire or choice responses cannot be assigned solely to the drug, independent of history, social conditions, education, smoking, cannabis exposure, personality, or other unmeasured factors. The investigators attempted demographic matching and statistical adjustment, but observational adjustment is not equivalent to randomization.

Some participant characteristics were relatively similar: both groups were 60% male, mean ages were approximately 35 years, and mean completed education was 12.40 versus 12.74 years. Other characteristics were not similar. Reported monthly income averaged $518 in users versus $1,160.70 in controls, and marijuana use was reported by 50% versus 8.5%, respectively. Those disparities were statistically significant in the source and were entered as covariates, rather than ignored.

Was methamphetamine administered as an experimental dose?

No. The investigators classified participants by historical active use and dependence criteria; they did not administer a controlled oral, intranasal, smoked, or injected methamphetamine dose. The experiment took place in approximately one 90-minute visit for most participants. Two people completed procedures across more than one visit because of time constraints. Neither a visit nor an individual choice trial becomes an additional biological subject.

A urine test provided biochemical support for the reported group assignment. The source describes a 500 ng/mL methamphetamine urinalysis cutoff, not a measured 500 ng/mL concentration in each subject. A cutoff defines the decision rule for a test, not the amount chemically confirmed in a person’s legal venous whole blood. Participants also underwent an alcohol breath screening; a positive reading led to discontinuation of that session. Neither screening procedure established a contemporaneous dose-response relationship between quantitatively assayed methamphetamine and discounting.

How were four different kinds of discounting measured?

Each task presented two hypothetical monetary alternatives on a computer. One option was an adjusting amount available to the participant close to the present, certain, or for oneself. The other option was a standard amount made distant by time, chance, or recipient. The standard values were $50 and $10,000 in the experimental procedure, and the investigators varied three distances or conditions for each type.

On each trial the adjusting sum moved according to previous choices. Six binary decisions were used to estimate one indifference point: the point at which a participant was approximately indifferent between options. The investigators then used three indifference points for each magnitude-by-discounting combination to fit a discount-rate model. The repeated choices produced parameter estimates; they were not separate participants, recorded cash transfers, or real-world observations of the hypothetical consequences.

What does future discounting test?

Future discounting asked whether a person preferred a smaller amount now over a larger amount later. The delayed options included approximately one month, six months, and five years. A high discount rate indicates that the person placed less present value on a later nominal sum. It does not directly identify why: uncertainty about the future, immediate financial need, trust in payment, the salience of a hypothetical amount, and valuation style may all influence choices.

Across monetary magnitudes, the methamphetamine group had a mean modeled log discount rate of −0.86, compared with −2.35 in controls; the reported group comparison was p < .001. The investigators also detected a group-by-reward-magnitude interaction, so the relative group difference was not identical at $50 and the larger hypothetical reward. Both magnitude-specific user-versus-control contrasts reached significance in this dimension.

How is past discounting different from failing a memory test?

For past discounting, participants evaluated an imagined reward received one month, six months, or five years earlier, against an amount imagined as received much more recently. It is a valuation exercise about temporal distance in retrospect; it is not a direct measurement of whether the person can accurately recall an event, identify a suspect, describe a conversation, or distinguish a real memory from a constructed one.

Across magnitudes, the user group had a mean logged discount rate of −0.58, compared with −2.62 among controls, with p < .001. As with future discounting, the group-by-magnitude interaction was significant and both magnitude-specific group contrasts were significant. These results support a group difference in hypothetical valuation of remotely past outcomes. They do not show that methamphetamine users necessarily give false testimony or cannot remember events.

What did probability discounting reveal?

The uncertain option offered a standard monetary amount with probabilities of 75%, 50%, or 10%, while the alternative was a smaller amount treated as certain. A participant who strongly discounts uncertain rewards may prefer certainty even when the uncertain alternative has a higher face value. That is not interchangeable with a generalized willingness to take physical risks, gamble irresponsibly, or drive dangerously.

The overall modeled log discount-rate mean was 1.44 in active users versus 0.55 in controls, a statistically significant group contrast (p < .005). However, the source reports a material qualification: the larger-magnitude group contrast was significant whereas the $50 group contrast was not. The group-by-magnitude interaction was significant. Accordingly, “methamphetamine users discounted every uncertain outcome significantly more” would overstate what was tested and found.

Did users assign less value to rewards given to other people?

Social discounting required each participant to rank personally known people from closer to more distant relationships, then compare money for oneself with money designated for the fifth, twentieth, or fiftieth ranked person. The task measured valuations of hypothetical transfers to others. It did not observe real generosity, parental care, prosocial behavior, empathy, theft, or honesty in an actual interpersonal encounter.

Mean log discount rates across magnitudes were −1.04 for users and −1.83 for controls (p < .01). The overall group effect was significant, but the group-by-magnitude interaction was nonsignificant. An exploratory small-reward group comparison reached significance, whereas the large-reward comparison did not (p = .076). Those three facts must be preserved together: a significant overall effect is not proof that every subdivision was significant.

Evidence table 1: Four discounting dimensions and their exceptions

Table interpretation: These are dimension-specific values from the original paper’s transformed discount-rate analyses, not monetary losses, observed acts, blood concentrations, effect sizes standardized across different experimental dimensions, or diagnostic thresholds. The study fitted separate models; a positive probability log rate is not directly comparable in ordinary units to a negative temporal log rate. Covariates included marijuana use and income, with available case counts varying for a small number of missing model data.

Why do the same group-level findings coexist with nonsignificant subtests?

Statistical statements have scopes. A group main effect pools information across levels of a model. An interaction asks whether the group difference changes with another factor, such as reward magnitude. A follow-up comparison examines one specific contrast and carries its own uncertainty. Those answers may differ without mathematical contradiction.

In the social task, for instance, the overall user-control comparison was significant but the interaction with monetary magnitude was not. The investigators nevertheless reported separate amount-specific follow-ups for continuity with the other tasks; one was significant and the other was not. Neither the significant small-outcome contrast nor the nonsignificant large-outcome contrast should be elevated into an assertion about all social decisions or all methamphetamine users.

Probability discounting illustrated an even sharper qualification. The user-control distinction was present for the larger hypothetical reward but did not attain significance for $50. The study therefore supports a pattern of different choices under its particular experimental amounts and chance levels, not an invariant psychological feature of every probability and reward size.

What did the additional questionnaires show?

The research included exploratory scales addressing future consequences, time orientation, sensitivity to rejection, delayed visual matching, and social allocation preferences. These serve a different evidentiary role from the primary four computerized discounting tasks. Their scores are not drug assays or independent samples. When a questionnaire did not distinguish groups, the correct description is nonsignificant, even when the raw group means differ slightly.

The user group reported a lower consideration-of-future-consequences score and lower future orientation, in line with parts of the researchers’ horizon hypothesis. But the delayed matching-to-sample task and social-value-orientation categories did not demonstrate significant differences. This is relevant to forensic evaluation: a theoretical account spanning valuation dimensions did not amount to uniform measurable deficits across memory, social motives, and every secondary psychological construct.

Evidence table 2: Secondary assessments include genuine null findings

The original second table also contained multiple other exploratory scores. Listing selected positive and negative comparisons side by side is more informative than selecting only a statistically significant scale. Many separate tests were conducted, and the original authors explicitly cautioned that exploratory correlations carried increased familywise-error potential; those tests were not a prespecified diagnostic battery for court or roadside screening.

Were all four psychological distances one unified trait?

Not demonstrably. Correlations within a given type of discounting and across reward magnitudes were generally substantial. Future and past discounting were associated, consistent with some shared temporal valuation processes. Yet the correlation matrix also contained nonsignificant cross-type pairs. For example, the smaller-reward probability and smaller-reward social discount parameters had a reported correlation approximately −0.01, not evidence of close tracking.

The authors regarded the overall pattern as supportive of a restricted-horizon framework while recognizing that the four tasks have distinct properties. Probability judgment incorporates subjective risk weighting; past reward valuation may depend on counterfactual imagination; social closeness depends on participant-specific relationships. Their different task demands and reward-magnitude effects are scientifically useful distinctions, not inconvenient results to erase.

Nor does correlation among two task scores prove a single neurochemical mechanism. No direct dopamine release, receptor occupancy, neural imaging, or dose-dependent methamphetamine assay was part of this experiment. Neurobiological mechanisms discussed in the paper were plausible interpretations informed by other literature, rather than newly measured outcomes in these 65 participants.

Which design features limit causal conclusions?

Most importantly, this was an observational group comparison. The groups differed in social and substance-use characteristics, including income and cannabis use. Adjusting for these measured variables cannot eliminate unobserved influences or determine whether differences predated heavy methamphetamine use, followed it, or were jointly shaped by other conditions. An active-user category is not equivalent to a random acute methamphetamine exposure.

All four discounting tasks used hypothetical money, with a large hypothetical option much greater than many participants’ ordinary income. Actual behavior involving family responsibilities, employment, health decisions, an emergency, or physical danger may have different incentives and constraints. Each magnitude-by-task estimate was based on only three indifference points, a compromise chosen to keep a demanding battery feasible. This may impair precision and sensitivity for some comparisons.

Magnitude order was counterbalanced between participants, but the order of discounting types and psychological distances was not. Fixed order can produce fatigue, practice, or carryover that is difficult to disentangle. Missing and nonconvergent parameter records further meant that model degrees of freedom varied. The authors also treated some exploratory associations without strict multiple-testing correction. These facts constrain how strongly small subgroup or correlation signals can be generalized.

Could a positive urine screen establish the methamphetamine level affecting a particular choice?

No. The investigators used urine screening to support whether volunteers belonged to the active-user or nonuser group. A stated 500 ng/mL screening cutoff should never be silently substituted for an actual reported individual concentration. The experiment did not publish paired chemically confirmed quantitative urine concentrations, a chiral methamphetamine analysis, plasma pharmacokinetics, or accurately timed human legal venous whole-blood methamphetamine measurements.

Urine is an excretory matrix; even a laboratory-confirmed urine analyte finding, without collection timing, renal context, method details, and an appropriate interpretive model, does not directly yield a contemporaneous venous whole-blood concentration. A urine-screening threshold is not a validated impairment cutoff. The alcohol screen was conducted on breath, not measured as ethanol in venous whole blood. Neither device result gives the missing individual parent-drug concentration or correlates it with hypothetical choice parameters.

For a method-focused explanation of why specimen categories cannot be swapped, see the independently published biological matrices guide; for an explanation of why a screening signal differs from specific analytical confirmation, see the published confirmatory drug testing guide. These are general methods references, not tests performed as study endpoints.

Does “more discounting” equal legal or clinical impairment?

No. The statistical result is a comparison of laboratory preference parameters between two samples. It is not a calibrated percentage probability of failing a field sobriety task, operating a vehicle unsafely, making a false statement, engaging in violence, or causing an accident. The study has no individual sensitivity/specificity calculation for any such target, no prespecified legal decision threshold, and no measured real-world driving outcome.

It would also be improper to describe every methamphetamine user as lacking self-control. The plotted bars represent distributions and group means; people within the same group can have different values. A significant group comparison does not make membership sufficient to determine the psychological state of an identified person at an identified moment. Information about a particular event would require independent incident reconstruction, actual observations, and analytically valid case-specific testing where available.

How should forensic experts distinguish behavior, screening, and toxicology?

Three evidentiary questions should remain separate. First, group behavior: how did participants choose between hypothetical outcomes under the experiment’s rules? Second, exposure classification: why were people included in the active methamphetamine group? Third, chemical quantitation: was a validated method used to measure a defined parent drug or metabolite in a named specimen at a known time? The Yi study speaks most directly to the first, uses historical reporting and screening for the second, and does not perform the third as a quantitative forensic endpoint.

The difference matters in litigation or clinical interpretation. A properly validated venous whole-blood mass-spectrometric drug concentration, if one exists in a separate case, does not become a behavioral choice or mental-state measurement. Conversely, a discounting score—even one acquired with good laboratory reproducibility—is not a substitute for blood pharmacology, a timeline of administration, signs on examination, or observations of actual conduct. Experts should not fuse these separate evidentiary categories without data demonstrating the link.

How does this study change the scientific conversation?

Its distinct contribution was to expand the idea of restricted horizons from future choices to three additional forms of psychological distance in active, non-treatment-seeking methamphetamine users. It found a recurring group direction across four outcome families while showing that reward magnitude, secondary memory testing, and some social or probability comparisons did not behave uniformly.

A follow-up investigation could test whether the pattern persists after matched abstinence intervals, objectively measured time since drug use, and better-controlled income or cannabis variables; compare real and hypothetical rewards; counterbalance task order; and evaluate validated longitudinal outcomes such as treatment retention. None of those experiments is contained retrospectively in this paper. Its strength lies in asking a wider, structured behavioral question, and its limitations define which claims remain unproven.

Frequently asked scientific and forensic questions

1. Did the experiment include 65 or more than 65 independent people?

It included 65 distinct adults: 30 active methamphetamine users and 35 nonusers. Repeated choice trials, monetary magnitudes, three distances, and four task types were within-person observations, not additional humans. Some individual task-model data were missing, so every reported statistic need not use an identical available-data denominator.

2. Was methamphetamine deliberately administered, and what was the dose?

No controlled methamphetamine dose was given. The user group had a history of active use and dependence; the study was not a pharmacokinetic dose-response trial. There is therefore no experimentally assigned mg dose, administration route, or drug-concentration curve that could be used to interpret an individual subject’s hypothetical choices.

3. Did urine testing reveal a precise methamphetamine concentration?

No individual quantitative concentration was supplied as a discounting endpoint. The reported 500 ng/mL urine methamphetamine cutoff supported screening or group classification, not a measured venous whole-blood value. The study also excluded sessions with positive alcohol breath screening rather than assaying blood ethanol.

4. Did every reward amount show a significant group difference?

No. The probability-discounting group contrast at the $50 amount was nonsignificant, and the social-discounting large-amount comparison was nonsignificant with p = .076. Future and past group contrasts were significant at both amounts. A significant overall group effect should not be transformed into a claim of uniform significant effects for all magnitudes.

5. Does the result prove that methamphetamine users cannot remember or testify accurately about the past?

No. Past discounting asked about valuation of hypothetical remotely past money, not accuracy of historical recall or veracity. A separate delayed matching-to-sample visual task showed no significant group difference (p = .19). Neither task validated a rule for assessing one person’s eyewitness memory or credibility.

6. Did the findings prove one universal brain impairment mechanism?

No. Different reward distances showed distinct magnitude patterns, and several cross-task correlations were nonsignificant. The investigators did not measure brain dopamine, fMRI activity, drug receptor binding, or direct chemical brain exposures in this sample. A restricted-horizon theory may guide new hypotheses but is not a demonstrated universal biochemical lesion or legal impairment test.

7. What can the study establish for an individual impaired-driving or injury case?

It can provide background on group-average valuation patterns in a narrowly defined observational cohort. It cannot determine a person’s methamphetamine dose, exact time of use, venous whole-blood concentration, contemporaneous driving fitness, motive, capacity to tell the truth, or responsibility for a collision. Those questions require distinct case-specific evidence and, when available, fit-for-purpose analytically validated testing.

Bottom line

Yi, Carter, and Landes found higher modeled discounting of hypothetical future, past, uncertain, and other-directed monetary outcomes in active methamphetamine users than in nonusing controls. The full result is more precise than a label of “impulsivity”: some amount-specific contrasts, secondary cognition and social-motive tests, and cross-dimensional correlations were genuinely nonsignificant. The study supports a group-level behavioral-economic hypothesis, not chemical evidence of acute methamphetamine effects or a conclusion about any individual person’s intoxication, credibility, or event causation. Read the original 2012 empirical article for the study’s methods, complete outcome tables, and stated limitations.